Carbonite, Inc. (CARB) provides backup, disaster recovery, high availability, and workload migration technology solutions in the United States.
Its solutions include Carbonite Safe that offers annual and multi-year cloud backup plans for individuals or businesses; and Carbonite Endpoint Protection that protects the data, which resides on an organization's computers, laptops, tablets, and smartphones.
The company's solutions also comprise Carbonite Hybrid Backup, which protects a customer's data footprint on-premise and in the cloud and enables recovery while version history stored in the cloud safeguards against disaster; Carbonite Cloud Backup that automatically backs up data to the cloud and keeps physical and virtual systems protected with point-in-time restore; and Carbonite Onsite Backup, a flexible data protection solution, which backs up and replicates data securely across a customer's own private network.
In addition, it offers Carbonite Availability that keeps critical business systems available on Windows and Linux servers; Carbonite Recover, a disaster recovery-as-a-service solution that securely replicates critical systems from a customer's primary environment to the cloud; Carbonite Migrate, which migrates physical, virtual, and cloud workloads to and from any environment with minimal risk and near-zero downtime; and Carbonite Email Archiving that provides MailStore offerings designed to meet the specific email archiving needs of customers in terms of performance, stability, functionality, and simplicity.
The company provides its solutions through distributors, value-added resellers, managed service providers, and global systems integrators.
Shares have moved above their 50-day moving average on heavy volume. We are now hearing rumors that company is a takeover target.
Entry Point: $17.00
Trading Range: $11.86 to $35.735
Stop Loss: $16.00
Target Price: $19.00
CARB closed at $22.90
InMode Ltd. (INMD) designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies.
The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.
It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions.
InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally.
On August 13th, Inmode (INMD) reported Quarter June 2019 earnings of $0.45 per share on revenue of $38.8 million. That pushed shares of this IPO into a bullish "cup and handle formation." Higher share prices are expected for this stock. The company reports November 7th.
Entry Point: $31.00
Stop Loss: $29.50
Trading Range: $13.06 - $32.50
Target Price: $34.10
INMD closed at $41.00
StoneCo Ltd. (STNE) provides financial technology solutions that empower merchants and integrated partners to conduct electronic commerce across in-store, online, and mobile channels in Brazil. It distributes its solutions, principally through proprietary Stone Hubs, which offer hyper-local sales and services; and technology and solutions to digital merchants through sales and technical personnel and software vendors.
As of June 30, 2018, the company served approximately 200,000 clients, which included digital, and brick-and-mortar merchants, primarily small-and-medium-sized businesses; and 95 integrated partners, such as global payment service providers, digital marketplaces, and integrated software vendors.
Shares of this recent IPO have formed a bullish "cup and handle" ahead of its earnings report on Monday afternoon. Analysts expect StoneCo earnings of 13 cents a share, up 550% vs. a year earlier, on revenue of $122.71 million, up 64% from a year ago. Higher share prices are expected for this stock. Note that Warren Buffet owns ten percent of yhr company.
Entry Point: $32.51
Stop Loss: $30.89
Trading Range: $16.14 - $34.50
Target Price: $35.76
STNE closed at $42.66
Genomic Health, Inc. (GHDX) provides actionable genomic information to personalize cancer treatment decisions worldwide.
It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy.
In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer.
The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals.
Shares have formed a bullish "cup and handle" and are on the verge of a breakout. The formation is supported by the stock's 50-day moving average.
Entry Point: $67.70
Stop Loss: $64.10
Trading Range: $26.54 - $72.83
Target Price: $74.50
GHDX closed at $87.30
Five Below, Inc. (FIVE) operates as a specialty value retailer in the United States.
It offers accessories, including novelty socks, sunglasses, jewelry, scarves, gloves, hair accessories, athletic tops and bottoms, and T-shirts, as well as beauty products comprising nail polish, lip gloss, fragrance, and branded cosmetics; and items used to complete and personalize living space, including glitter lamps, posters, frames, fleece blankets, pillows, candles, incense, and related items, as well as provides storage options for the customer's room and locker.
The company also provides sport balls; team sports merchandise and fitness accessories, such as hand weights, jump ropes, and gym balls; games, including name brand board games, puzzles, toys, and plush items; and pool, beach and outdoor toys, games, and accessories.
In addition, it offers accessories, such as cases, chargers, headphones, and other related items for PCs, cell phones, and tablet computers; books, video games, and DVDs; craft activity kits; arts and crafts supplies that consist of crayons, markers, and stickers; and trend-right items for school comprising backpacks, fashion notebooks and journals, novelty pens and pencils, and everyday name brand items.
Further, the company provides party goods, gag gifts, decorations, and greeting cards, as well as every day and special occasion merchandise products; assortment of classic and novelty candy bars, movie-size box candy, and gum and snack food; chilled drinks through coolers; and seasonally-specific items used to celebrate and decorate for events, such as Christmas, Easter, Halloween, and St. Patrick's Day. It primarily serves teen and pre-teen customers. As of October 20, 2017, it operated approximately 600 stores in 32 states.
Shares have formed a bullish "cup and handle" and are expected to head higher. The formation is supported by the stock's 50-day moving average.
Entry Point: $74.75
Stop Loss: $71.00
Target Price: $82.23
52-Weeks Trading Range: $44.30 to $78.28
FIVE closed at $94.00
Puma Biotechnology, Inc. (PBYI) is a biopharmaceutical company.
The firm focuses on the development and commercialization of products to improve cancer care.
Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)).
The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds.
Shares have formed a bullish "flag" ahead of FDA's meeting on the company's brast cancer drug. The FDA has scheduled a May 24 Advisory Committee meeting for Puma’s neratinib in extended adjuvant treatment of “HER2” early stage breast cancer. In its Q1 earnings report last night, the company confirmed that “we look forward to presenting” at the May 24 meeting.
In a post-earnings research note, Citi’s analyst highlights that Puma accelerated plans for final five-year data from the ” #ExteNET ” neratinib trial to Q2 from the second half, as it will be used during the drug’s May 24 #AdComm. The analyst confirmed with Puma that additional data from the “CONTROL” prophylactic trial will also be presented at the meeting.
Notably, the analyst says he “noticed” that Puma appears to be actively hiring for commercial operations, with the company’s website now showing 18 job listings for roles within outreach, commercial supply chain, market access, reimbursement, and other areas. Though critics may interpret the news as signaling that Puma doesn’t expect to be acquired, the analyst counters that such an argument “doesn’t work too well tactically,” as the stock should gain at least 100% on what he calls an “expected positive” AdComm. Higher share prices are expected for this stock.
52-Weeks Trading Range: $27.64 - $73.27
Entry Point: $37.80
Stop Loss: $35.90
Target Price: $41.58
PBYI closed at $69.35
Ingram Micro Inc. (IM) distributes information technology (IT) products; and provides supply chain and mobile device lifecycle services worldwide.
The company offers printers, scanners, displays, projectors, monitors, panels, mass storage, and tape products; digital signage products; digital cameras and video disc players, game consoles, televisions, audio, small appliances, media management, and home control products; barcode/card printers, AIDC scanners and software, and wireless infrastructure products; Internet protocol video surveillance, security and fire alarm systems, and access control smart cards; processors, motherboards, hard drives, and memory products; and ink and toner supplies, paper, carrying cases, and anti-glare screens.
It also provides rack, tower, and blade servers; desktops; portable personal computers and tablets; and business application, operating system, entertainment, security, storage, and virtualization software products, as well as middleware and developer software tools.
In addition, the company offers switches, hubs, routers, wireless local area networks, wireless wide area networks, network interface cards, cellular data cards, network-attached storage, and storage area networks; VoIP, communications, modems, phone systems, and video/audio conferencing; and firewalls, VPN, intrusion detection, and authentication devices and appliances.
Further, it provides mobile handsets, tablets, navigation devices, aircards, SIM cards, flash memory, and other mobile companion products; supply chain, bid and inventory management, integration, technical support, training, financial and credit, marketing, marketing agency, business intelligence and analytics, e-commerce, managed, cloud, managed print, solution center, professional, and mobility device lifecycle services. The company sells its products to resellers of IT products and services through sales representatives.
The firm reports its quarterly results on February 25th. Ahead of that, shares have move above their 200-day moving average (shown in green). Higher share prices are expected for this stock.
52-Weeks Trading Range: $22.54 - $32.09
Entry Point: $28.30
Stop Loss: $26.75
Target Price: $31.15
IM closed at $36.10
This stock was first featured July 2013 at $34.
YY Inc. (YY) operates an online social platform in the Peoples Republic of China.
It provides YY Client, a personal computer based user software that offers real-time access to user-created online social activities groups.
The company also offers Web-based YY that enables users to conduct real-time interactions on the Web without any downloads or installations; and Mobile YY, a smartphone application.
In addition, it operates Duowan.com, a game media Website that provides information on online games and other resources for users and online game players.
Shares have formed a bullish "cup and handle" and higher share prices are expected for this stock. The Company reports earnings tomorrow, and we are now hearing rumors that the firm will post very strong results. This morning's weakness due to the Ukraine sitatuion, should offer a better entry point for this stock.
52-Week Trading Range: $15.26 - $77.90
Entry Point: $72.50
Stop Loss: $68.88
Target Price: $79.75
YY has reached our target price. We are riding it higher as we believe earnings will be strong. YY last traded at $81.00.
YY Inc. reports Q4 EPS 53c, consensus 46c - Reports Q4 revenue $101.1M, consensus $84.48M. YY Inc. sees FY14 revenue up 98%-102% to RMB 625M-RMB 635M.
We are closing the positon at $94.00 in after hours trading.
Forest Laboratories (FRX) develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe.
It principally offers Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic for the treatment of hypertension; Savella for the management of fibromyalgia; Teflaro for the treatment of adults with skin and skin structure infections, and community-acquired bacterial pneumonia; Daliresp to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD; and Viibryd for the treatment of adults with major depressive disorder (MDD).
The company has products under new drug application review by Food and Drug Administration comprising Aclidinium for the maintenance treatment of COPD; and Linaclotide for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. It also develops ceftaroline/avibactam combination, which is under Phase III clinical trials for complicated intra-abdominal infections, as well as has completed Phase II clinical trials for complicated urinary tract infections; and Cariprazine that is in Phase III clinical trials for the treatment of acute exacerbation of schizophrenia and acute mania associated with bipolar disorder.
In addition, the company develops Levomilnacipran, which is under Phase III clinical trials for the treatment of MDD; GRT 6005 that is under Phase II clinical trials for nociceptive and neuropathic pain; TTP399, which is under Phase II clinical trials for the treatment of Type II diabetes; and RGH-618 that is under Phase I clinical trials for the treatment of anxiety, depression, and other central nervous system conditions.
Shares have formed a bullish "flag" after the firm reported strong quarterly results and guided higher going forward! Higher share prices are expected for this stock.
52-Week Trading Range: $35.22 - $72.40
Entry Point: $64.95
Stop Loss: $61.70
Target Price: $ 71.44
We are taking profits on FRX. Position closed in pre-market trading at $93.15 for a 43% gain.
Generac Holdings (GNRC) designs, manufactures, and markets a range of generators and other engine powered products for the residential, light commercial, industrial, and construction markets in the United States and Canada.
It offers generators and other products fueled by natural gas, liquid propane, gasoline, diesel, and Bi-Fuel under the Generac and Magnum brands. The companys product line includes residential power products, commercial and industrial power products, and other products. Its residential power products comprise automatic residential standby generators that range in output from 6kW to 60kW; air-cooled residential standby generators, which range in outputs from 6kW to 20kW; and liquid-cooled generators that range in outputs from 20kW to 60kW.
The residential power product line also includes portable generators consisting of GP series ranging from 1,850W to 17,500W for homeowners; the XG series ranging from 4,000W to 10,000W for the premium homeowner market; the XP series ranging from 4,000W to 8,000W for the professional contractor market; and the iX series ranging from 800W to 2,000W for the recreational market.
The companys industrial and commercial power products comprise light-commercial standby generators ranging from 22kW to 150kW for grocery stores, convenience stores, restaurants, gas stations, pharmacies, retail banks, and healthcare facilities; single-engine industrial generators, which range in output from 10kW to 600kW; and generator systems ranging from 20kW air-cooled generators to 3mW modular power system for the telecommunications market, as well as aftermarket service parts and RV generators.
The company sells its generators through independent residential and industrial dealers, wholesalers, national accounts, private label arrangements, retailers, catalogs, e-commerce merchants, equipment rental companies and dealers, and construction companies. Shares have formed a bullish "flag" after the firm guided higher. We expect higher prices for the stock.
52-Week Trading Range: $18.35 - $30.61
Last Trade: $25.88
Stop Loss: $24.50
Target Price: $28.45
GNRC reported great earnings and guided higher. We are closing the position at $32.88
Select Medical Holdings Corporation (SEM) operates specialty hospitals and outpatient rehabilitation clinics in the United States. The company's Specialty Hospitals segment offers long term acute care hospital services and inpatient acute rehabilitative hospital care. This segment provides services for various medical conditions, such as respiratory failure, neuromuscular disorders, traumatic brain and spinal cord injuries, strokes, non-healing wounds, cardiac disorders, renal disorders, and cancer. As of December 31, 2011, it operated 110 long term acute care hospitals and 9 inpatient rehabilitation facilities in 28 states. The Outpatient Rehabilitation segment operates clinics; and provides physical, occupational, and speech rehabilitation services. It offers medical rehabilitation services on a contract basis at nursing homes, hospitals, assisted living and senior care centers, schools, and worksites. This segment also provides specialized programs, such as functional programs for work related injuries, hand therapy, and athletic training services. As of December 31, 2011, it operated 954 outpatient rehabilitation clinics in 32 states and the District of Columbia. We are now hearing rumors of good news for this company. One of the rumors states that this stock will be named by the leading stock advisory service as one of its "top picks." This service is widely followed by mutual funds and institutional money managers. These investors have portfolios that mimic recommendations of this service. Their naming of the stock should lead to additional demand for the shares. Shares are heading higher in a bullish "cup & handle" and are expected to move higher in this formation. The stock has a 52-week trading range of $5.48 - $11.06. Shares last traded at $10.59. Should you decide to take a position, wait for the morning volatility to wear off and use a stop-loss of $10.06 (five percentage points below your purchase price.) Be sure to use a limit order and not a market order. Keep in mind that our price target is 10% higher than your purchase price.